Leucyl tRNA synthetase ameliorates cholestatic liver injury by inhibiting integrated stress response in mice Authors: Pengfei Yan, Dongsheng Yu, Qianyi Wei, Hongwei Tang, Ruolin Tao, Bing Yan, Jiakai Zhang, Jihua Shi, Wenzhi Guo, Shuijun Zhang Published: 2026 ABSTRACT Aminoacyl-tRNA synthetases, as pivotal enzymes in protein biosynthesis, have been linked to the development of certain diseases when specific isoforms are dysregulated. However, the involvement of leucyl-tRNA synthetase (LARS) in hepatic pathologies remains unexplored. In this study, a marked upregulation of LARS was observed in cholestatic liver tissues. Mice with liver-specific LARS knockdown manifested substantially attenuated hepatic injury, evidenced by reductions in serum alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase levels, as well as dysregulated bile acid homoeostasis, diminished hepatic necrosis, fibrosis, and hepatocyte apoptosis. Conversely, hepatic overexpression of LARS resulted in exacerbated liver injury. To mimic cholestatic injury in vitro, AML-12 cells were exposed to taurocholic acid (TCA), where it was found that LARS deficiency alleviated TCA-induced cellular damage and apoptosis. Mechanistically, bile acids were found to induce an integrated stress response (ISR) via up-regulating the phosphorylation of general control nonderepressible (GCN) 2 levels. Notably, LARS deficiency was shown to attenuate the TCA-induced GCN2 phosphorylation upregulation, while no modulatory effect was detected on GCN2 expression in the absence of TCA. Furthermore, BDL decreased the hepatic leucine contents and tRNA cahrging ratio, which was reversed by LARS knockdown. GCN2 knockdown reversed the effect of LARS overexpression on AML-12 cell viability. Collectively, these findings delineate a regulatory role for LARS in modulating cholestatic liver injury, likely through the suppression of leucine-tRNA-GCN2 activation and ISR signaling pathway.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-54477-1. Introduction Cholestatic liver injury (CLI) is predominantly attributed to intrahepatic cholestasis, a pathological condition marked by systemic and intrahepatic bile acid (BA) retention, which arises from factors including pharmacological interventions, immune-mediated inflammation, viral pathogens, or genetic anomalies1. Excessive accumulation of BAs has been shown to not only provoke direct hepatocellular injury and apoptosis at elevated concentrations but also initiate hepatic and intestinal inflammatory responses through diverse BA receptor-mediated pathways2. Additionally, the extravasation of BAs contributes to multifocal biliary strictures and obstructions within both intrahepatic and extrahepatic bile ducts, often manifesting as a progressive and destructive form of cholangitis that clinically presents with symptoms such as fatigue and pruritus3, and is referred to as primary biliary cholangitis or primary sclerosing cholangitis. Consequently, cholestatic liver disease constitutes a formidable challenge in clinical practice, posing significant threats to patient prognosis and long-term survival. Ursodeoxycholic acid (UDCA) remains the primary therapeutic agent sanctioned by the Food and Drug Administration for various cholestatic hepatopathies and is extensively employed as a supportive intervention for CLI4. Nevertheless, UDCA administration has frequently been correlated with limited therapeutic efficacy and the occurrence of adverse reactions, including diarrhea, nausea, and urticaria5. Therefore, comprehensive clarification of the molecular mechanisms underlying BA-induced hepatic injury, along with the identification of innovative therapeutic modalities and pharmacological targets for CLI, is regarded as imperative. These investigations are anticipated to provide a theoretical framework for the advancement of more efficacious pharmacotherapies aimed at the prevention and treatment of CLI, thereby bearing substantial clinical relevance. The integrated stress response (ISR) constitutes a eukaryotic intracellular signaling cascade activated by both extrinsic stimuli (e.g., amino acid or oxygen deprivation) and intrinsic perturbations (e.g., protein misfolding or proteotoxicity), serving a regulatory function in the pathogenesis of various complex diseases6. Currently, limited insight exists regarding the extent to which ISR interacts with other intracellular signaling networks to influence cell fate determination and physiological outcomes. Functionally, ISR modulates cellular stress responses through a biphasic mechanism that balances biosynthetic activity with environmental stressors, thereby facilitating either the restoration of cellular homeostasis or the induction of apoptosis in irreversibly compromised cells7. This dynamic regulation of equilibrium carries substantial biological significance across a spectrum of physiological and pathological contexts. Prior investigations have demonstrated that ISR activation may be triggered by oncogenic signals, hepatitis C virus infection, and somatotroph axis dysregulation, all of which affect nutrient sensing and translational control in hepatocellular carcinoma (HCC), viral hepatitis, and nonalcoholic fatty liver disease8,9. Although these earlier findings have established a relationship between ISR activation and the cellular adaptation to diverse signal-driven hepatic diseases, the involvement of BA accumulation in the modulation of ISR activation during CLI remains undetermined. Aminoacyl-tRNA synthetases (ARSs) are a family of highly conserved enzymes responsible for catalyzing the ligation of specific amino acids to their cognate tRNAs in the process of protein synthesis. In humans, the 20 standard amino acids are matched by a corresponding set of 20ARSs. These enzymes are pivotal in ensuring the fidelity of protein synthesis by catalyzing the ligation of specific amino acids to their cognate tRNAs. Beyond this canonical function, ARSs are intricately linked to the pathophysiological processes of various human diseases. For instance, histidyl-tRNA synthetase (HARS) charges tRNA with histidine, and mutations in the HARS gene can lead to peripheral neuropathies such as Charcot-Marie-Tooth disease (CMT), primarily through gain-of-toxic-function mechanisms10. Tryptophanyl-tRNA synthetase (WARS) exemplifies the concept of moonlighting functions; in addition to its role in tryptophan activation, it can be secreted to participate in angiogenesis and immune modulation11. Similarly, seryl-tRNA synthetase (SerRS) exhibits non-canonical regulatory activity by translocating to the nucleus and directly modulating the transcription of vascular development-related genes, thereby linking amino acid metabolism to the regulation of angiogenesis12. Leucine-tRNA synthetase (LARS) is responsible for the ligation of leucine to their corresponding tRNAs, prior research has identified LARS as a component associated with mammalian target of rapamycin complex 1 (mTORC1) through leucine sensing, functioning to activate mTORC1 by catalyzing the conversion of RagDGTP to RagDGDP13,14. In recent years, a growing body of evidence has highlighted its association with neurodegenerative disorders. In cases of Alzheimer’s disease, LARS expression is downregulated, and its dysfunction has been linked to leukodystrophy characterized by a mitochondrial signature15. Moreover, alterations in LARS activity have been implicated in modulating energy metabolism, epigenetic regulation, and redox homeostasis, all of which may subsequently affect cellular proliferation and apoptosis16,17. Nonetheless, its involvement in hepatic pathophysiology remains insufficiently characterized. To clarify the functional role of LARS in CLI and its association with the ISR signaling pathway, both in vivo and in vitro models were employed to examine LARS’s regulatory effects on ISR dynamics. Bile duct ligation (BDL) was performed in mice to systematically assess whether alterations in LARS expression, either through knockdown or overexpression, modulate the progression of obstructive CLI and to further examine changes in ISR-related signaling components and their downstream molecular mechanisms. These findings establish a theoretical foundation indicating LARS as a potential therapeutic target for CLI treatment through the inhibition of the ISR signaling pathway. Materials and methods Reagents Taurocholic acid (TCA, #T9034) was acquired from Sigma-Aldrich Corp. (St. Louis, MO, USA). The HiScript II 1st Strand cDNA Synthesis Kit (#R212-01), ChamQ Universal SYBR qPCR Master Mix Kit (#Q711-02), and ExFect Transfection Reagent (#T101-01) were procured from Vazyme (Nanjing, China). Cell Counting Kit-8 (CCK-8, #HY-K0301), ISRIB (#HY-12495 A), Tunicamycin (Tm, #HY-A0098) and Thapsigargin (Tg, #HY-13433) were procured from Med Chem Express (Shanghai, China). Expression vectors including pcDNA3.1(+)-Flag-tagged mouse LARS, along with siRNA and shRNA constructs targeting mouse LARS and GCN2, were supplied by Shanghai OBiO Biotech Co., Ltd. (Shanghai, China). Reactive Oxygen Species Assay Kit for Superoxide Anion with DHE kits (#S0064S) was procured from Beyotime Bioengineering Institute (Shanghai, China). Total bile acids content assay kit (TBA, #BC6300) was purchased from Solarbio (Beijing China). Animal Male C57BL/6J mice (6–8 weeks old) were procured from Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China) and kept under specific pathogen-free conditions at the Laboratory Animal Center of Zhengzhou University. Environmental parameters were controlled at 22 ± 2 ℃, 50% relative humidity, and a 12-hour light/dark cycle, with unrestricted access to food and water. BDL surgery was executed according to previously published protocols18,19. To investigate the involvement of LARS in CLI, pcADV-EF1-mNeonGreen-CMV-3×Flag vectors encoding LARS or vector control, pAAV-U6-shRNA-CBh-EGFP-WPRE vector with serotype AAV2/8 containing LARS shRNA or shNC were constructed by Shanghai Obio Technology Corp., Ltd. The sequences used for scrambled shRNA and shLARS were 5′-TTCTCCGAACGTGTCACGTAA-3′ and 5′-GCTTATGACCATCGTGCTAAT-3′, respectively. C57BL/6J mice received tail vein injections of pAd-Vector or pAd-LARS for 1 week, pAAV-shNC or pAAV-shLARS for 3 weeks, followed by BDL performed for an additional 7 days. Mice were anesthetized with 1% pentobarbital via intraperitoneal injection at a dosage of 0.6 ml/100 g prior to BDL. Upon conclusion of the experiment, animals were euthanized with an overdose of the inhalational anesthetic isoflurane (#R510-22-2, Ruiwode Life Technology Co., Ltd, Shenzhen, China). Following anesthesia, both liver tissue and serum samples were collected and preserved at − 80 ℃. RNA sequencing procedures were executed as previously described20. The weight of the mice involved in the experiment was 22–26 g. All experimental procedures received ethical approval from the Experimental Animal Ethics Committee of The First Affiliated Hospital of Zhengzhou University (No. 2021-KY-0990-002). All methods were carried out in accordance with relevant guidelines and regulations. All methods are reported in accordance with ARRIVE guidelines. Histopathological analysis After the treatment protocol conclusion, the extracted liver samples underwent fixation in 10% formalin solution. These tissue specimens were processed through paraffin embedding and cut to obtain 5 μm-thick sections. H&E staining and Sirius red staining were employed to evaluate hepatocyte necrosis and collagen fiber deposition, respectively. Immunohistochemical (IHC) staining and TdT-mediated dUTP-biotin nick end labeling (TUNEL) staining was conducted using an anti-cleaved caspase-3 antibody or Cy3-dUTP labeling mix to assess cellular apoptosis. Microscopic observations were documented utilizing a CX33 microscope (Olympus, Tokyo, Japan). Biochemical assays The assay kits of alanine aminotransferase (ALT, #C009-1-1), aspartate aminotransferase (AST, #C010-2-1), and alkaline phosphatase (ALP, #A059-1-1) enzymatic activity purchased from Jiancheng Bioengineering Institute (Nanjing, China) were utilized to quantify the liver function according to the supplier’s protocols. TBA contents in serum and hepatic were quantified using commercial kits. Liver BAs profiles analysis and targeted amino acid (AA) metabolomics The content of 24 BAs in the liver tissues were measured using UHPLC/MS according to the previously reported method21. For amino acid analysis by UPLC-HRMS, Liver tissues were homogenized and extracted with 0.1 M HCl. After filtration, the filtrate was derivatized. The mixture was heated at 55℃ for 10 min, and cooled prior to injection. Chromatographic separation was performed on a Vanquish UPLC system equipped with a ChromCore 120 C18 column (100 × 4.6 mm, 3 μm) maintained at 50℃. The mobile phase consisted of water and acetonitrile, both containing 0.1% formic acid. Mass spectrometric detection was carried out on a Q Exactive hybrid Q-Orbitrap (Thermo Fisher Scientific) with a heated electrospray ionization (HESI) source in Full MS mode. Key source parameters were: spray voltage, 3.0 kV; sheath gas, 40 arb; auxiliary gas, 10 arb; sweep gas, 0 arb; capillary temperature, 320℃; and heater temperature, 350℃. Data acquisition and processing were performed using Xcalibur 4.1 and TraceFinder 4.1 Clinical software, respectively. RNA seq and gene expression profile data 12 liver tissues from Sham and BDL 7 d groups were collected and lysed with TRIzol reagent. RNA was qualified by NanoDrop2000 (Thermo, USA) and subsequently screened on Novaseq 6000 Sytem platform (Illumina Inc., USA). The threshold was fold change > 1.5 and P < 0.05. The datasets generated and analysed during the current study are available in the SRA repository, with accession No. PRJNA1372930 (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1372930). GSE166867, GSE36066, GSE182235 and GSE186444 datasets analyzed in this study were obtained from the GEO database (https://www.ncbi.nlm.nih.gov/geo/). Among them, Liver tissue harvested on day 7 after BDL and Sham from GSE166867 were analyzed. The GEO2R online analysis tool (https://www.ncbi.nlm.nih.gov/geo/geo2r/) was used to detect the differentially expressed genes (DEGs). Cell culture The mouse AML-12 hepatocyte lineage was procured from the National Collection of Authenticated Cell Cultures (Shanghai, China) and grown at 37℃ under controlled conditions with 5% CO2 in a moisture-regulated environment. The cells were cultivated in DMEM/F-12 medium comprising 100 U/mL penicillin, 100 mg/mL streptomycin, 1% ITS Liquid Media Supplement (Sigma, I3146), 40 ng/mL dexamethasone, and 10% fetal bovine serum (FBS, Gibco, Carlsbad, CA, USA). To conduct LARS overexpression and knockdown studies, the cells were placed into 6-well plates at 2.0 × 105 per well and left overnight for attachment. The LARS overexpression vector, LARS or GCN2 siRNA were delivered into cells utilizing ExFect Transfection Reagent with a 48 h incubation period. Subsequently, the cells were collected for further examination. Cell viability assay Cell viability was assessed utilizing the CCK-8 per the supplier’s protocols. Briefly, 5,000 cells were placed into each well of 96-well plates and exposed to specified treatments. Subsequently, the culture medium was switched to 90 µL of new medium with 10 µL CCK-8 solution, allowing incubation for 1 h. Absorbance was recorded at 450 nm utilizing a microplate spectrophotometer (DeNovix, USA). Oxidative stress analyses To evaluate cellular oxidative stress, intracellular reactive oxygen species (ROS) levels were determined utilizing a Dihydroethidium (DHE) probe and visualized under a fluorescence microscope. Briefly, cells underwent incubation with DHE for 30 min, succeeded by three phosphate-buffered saline (PBS) washing steps, before being suspended again in 1 mL of DMEM/F12 medium. Fluorescence signals were subsequently examined using a fluorescence microscope. Western blot Protein samples were isolated from liver tissues and AML-12 cells, separated by SDS-PAGE, and transferred to PVDF membranes. The membranes were then blocked with 5% (w/v) skim milk in TBST for 1 h, followed by overnight incubation with primary antibodies at 4℃. After extensive washing with TBST, the membranes were incubated with appropriate secondary antibodies for 1 h. Protein bands were visualized using an enhanced chemiluminescence (ECL) reagent and imaged on a chemiluminescence imaging system. RT-qPCR RNA was procured from liver tissues or cultured cells utilizing TRIzol reagent (#15596-026, Invitrogen, Carlsbad, CA, USA), succeeded by conversion to cDNA using HiScript II Q RT SuperMix (R223-01, Vazyme, Nanjing, China). RT-qPCR analysis was carried out on a QuantStudio 5 Real-Time PCR System (Applied Biosystems, Waltham, MA, USA). The design and synthesis of primers were accomplished by Tsingke Biotechnology Co., Ltd. (Beijing, China), with specific sequences depicted in Table 1. The internal control gene used for normalization was 36B4 (Table 2). Table 1Primer sequences for RT-qPCR.GeneForward (5’-3’)Reverse (5’-3’) HARS GAGGAGCTGGTACGACTCCAGGCGTTTGAAACAGCGGATG WARS AAAGCCAGCGAGGATTTTGTGAGCTCTTTGTCAATTTTGCTGC KARS GGGCAGAATGGGGTCAGAGTTGTGGAGCGTTGTGAAAGGA SerRS CGGGTGGATAAAGGAGGGGATGCCCGAAATCTGCATCGTC LARS AGAAACAGCTAAACCAGACTGCCGGCTTGACTTCGGATCTTGTA Tnf-α GATCGGTCCCCAAAGGGATGCCACTTGGTGGTTTGTGAGTG Il-1β TGCCACCTTTTGACAGTGATGATGTGCTGCTGCGAGATTTG Il-6 ATGTGCTGCTGCGAGATTTGGTGACTCCAGCTTATCTCTTGGT PKR GCTGGAAATGCACCAAAAGATGGCTTGTCCGCACTGTCCAT HRI GAGGAGCTGGTACGACTCCAGGCGTTTGAAACAGCGGATG ATF4 CCTTCGACCAGTCGGGTTTGCTGTCCCGGAAAAGGCATCC CHOP CTGGAAGCCTGGTATGAGGATCAGGGTCAAGAGTAGTGAAGGT ERdj4 ATAAAAGCCCTGATGCTGAAGCGCCATTGGTAAAAGCACTGTGT Gcn2 TCCCACTGACGTCCCCTAACAGGTGGGCATTTAACCCTCAG 36B4 AAGCGCGTCCTGGCATTGTCTCCGCAGGGGCAGCAGTGG Table 1Primer sequences for RT-qPCR.GeneForward (5’-3’)Reverse (5’-3’) HARS GAGGAGCTGGTACGACTCCAGGCGTTTGAAACAGCGGATG WARS AAAGCCAGCGAGGATTTTGTGAGCTCTTTGTCAATTTTGCTGC KARS GGGCAGAATGGGGTCAGAGTTGTGGAGCGTTGTGAAAGGA SerRS CGGGTGGATAAAGGAGGGGATGCCCGAAATCTGCATCGTC LARS AGAAACAGCTAAACCAGACTGCCGGCTTGACTTCGGATCTTGTA Tnf-α GATCGGTCCCCAAAGGGATGCCACTTGGTGGTTTGTGAGTG Il-1β TGCCACCTTTTGACAGTGATGATGTGCTGCTGCGAGATTTG Il-6 ATGTGCTGCTGCGAGATTTGGTGACTCCAGCTTATCTCTTGGT PKR GCTGGAAATGCACCAAAAGATGGCTTGTCCGCACTGTCCAT HRI GAGGAGCTGGTACGACTCCAGGCGTTTGAAACAGCGGATG ATF4 CCTTCGACCAGTCGGGTTTGCTGTCCCGGAAAAGGCATCC CHOP CTGGAAGCCTGGTATGAGGATCAGGGTCAAGAGTAGTGAAGGT ERdj4 ATAAAAGCCCTGATGCTGAAGCGCCATTGGTAAAAGCACTGTGT Gcn2 TCCCACTGACGTCCCCTAACAGGTGGGCATTTAACCCTCAG 36B4 AAGCGCGTCCTGGCATTGTCTCCGCAGGGGCAGCAGTGG Primer sequences for RT-qPCR. Table 2List of antibodies.Primary antibodiesDilutionCompany (Cat. No.)LARS1:1000Abcam (ab127754)P-GCN2 (Thr899)1:1000Proteintech (82835-3-RR)GCN21:1000Proteintech (27944-1-AP)P-IRE1α1:1000Novus Biologicals (NB100-2323)IRE1α1:1000Cell Signaling Technology (3294)XBP1s1:1000Cell Signaling Technology (40435)XBP1t1:1000Abcam (ab220783)CHOP1:1000Cell Signaling Technology (2895)ATF41:1000Cell Signaling Technology (11815)P-eIF2α1:1000Cell Signaling Technology (3742)eIF2α1:1000Proteintech (11233-1-AP)GAPDH1:5000Proteintech (60004-1-Ig) Table 2List of antibodies.Primary antibodiesDilutionCompany (Cat. No.)LARS1:1000Abcam (ab127754)P-GCN2 (Thr899)1:1000Proteintech (82835-3-RR)GCN21:1000Proteintech (27944-1-AP)P-IRE1α1:1000Novus Biologicals (NB100-2323)IRE1α1:1000Cell Signaling Technology (3294)XBP1s1:1000Cell Signaling Technology (40435)XBP1t1:1000Abcam (ab220783)CHOP1:1000Cell Signaling Technology (2895)ATF41:1000Cell Signaling Technology (11815)P-eIF2α1:1000Cell Signaling Technology (3742)eIF2α1:1000Proteintech (11233-1-AP)GAPDH1:5000Proteintech (60004-1-Ig) List of antibodies. Annexin V-APC/PI flow cytometry assay Cells cultured in 12-well plates were harvested for apoptosis analysis. The culture medium was first aspirated and transferred into labeled Eppendorf tubes. A PBS rinse was performed on the specimens, followed by application of 0.25% trypsin (Gibco, USA) for enzymatic breakdown. The process was halted through the introduction of the previously saved medium. The cellular mixture underwent centrifugation at 2,000 rpm for 10 min. Post-centrifugation, specimens received an additional PBS wash, and the liquid phase was eliminated. Subsequently, each sample vessel received 100 µL of cell flow buffer, 2.5 µL Annexin V-APC, and 2.5 µL PI, followed by gentle mixing. A trio of control vessels was established: blank control, Annexin V-APC singular, and PI singular. The specimens were maintained at ambient temperature in the dark for 10 min. Following this period, 500 µL PBS was incorporated into each vessel, and specimens were transferred to ice immediately. Analysis via flow cytometry was executed promptly using a flow cytometer (BD, USA). Individual tRNA acylation PCR Total RNA was extracted from mouse liver tissues using TRIzol reagent (Invitrogen) under acidic conditions (pH 4.5) to preserve the labile ester bond of aminoacyl-tRNAs. Small RNA fractions (< 200 nt) were enriched using miRNAeasy kits (Qiagen) according to the manufacturer’s instructions. To remove base methylations that impede reverse transcription, 500 ng of small RNA was treated with recombinant AlkB enzyme (NEB) in the presence of 150 µM α-ketoglutarate, 2 mM ascorbate, and 100 µM (NH4)2Fe(SO4)2 at 37℃ for 2 h. Subsequently, the samples were subjected to periodate oxidation and β-elimination to distinguish acylated from deacylated tRNAs: oxidized samples were incubated in 100 mM sodium acetate (pH 4.5) at 45℃ for 1 h, followed by dephosphorylation with T4 polynucleotide kinase to remove the 3’-phosphate from the resulting CC ends. A pre-adenylated DNA linker was ligated to the 3’-end of the treated RNAs using T4 RNA ligase 2 at 25℃ for 2 h. Reverse transcription was performed using SuperScript IV (Invitrogen) with a primer complementary to the linker sequence. The resulting cDNA was quantified by TaqMan MGB qPCR using two probes specific to the tRNA of interest: one FAM-labeled probe targeting the CCACCA sequence (representing originally acylated tRNA) and one VIC-labeled probe targeting the CCACCN sequence (representing originally deacylated tRNA). The cycling conditions were 95℃ for 10 min, followed by 40 cycles of 95℃ for 15 s and 60℃ for 1 min. The charging ratio was calculated as the signal of FAM/(FAM + VIC), normalized to a standard curve generated from synthetic tRNA DNA templates with defined CCA/CC ratios22. Statistical analysis Continuous variables were denoted as mean ± SEM. Statistical differences between the two groups were assessed utilizing Student’s t-test. For comparisons involving more than two groups, one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was performed. Statistical significance was established at P < 0.05. Results LARS expression is upregulated in cholestatic livers Liver tissues from mice were collected on day 7 following BDL surgery for transcriptome sequencing. The analysis identified a total of 3,479 DEGs in the BDL 7-day group versus the Sham group, comprising 1,917 upregulated and 1,562 downregulated genes. Representative differential expression volcano plots are presented in Fig. 1A. KEGG pathway enrichment analysis23–25 demonstrated that the DEGs were predominantly involved in biological processes like choline metabolism, sphingolipid metabolism, glycerophospholipid metabolism, aminoacyl-tRNA biosynthesis, amino acid biosynthesis, and 2-oxoglutarate metabolism (Fig. 1B). Fig. 1LARS was upregulated in BDL mouse liver tissues. (A,B) Liver tissues were collected 7 days after sham or BDL surgery (n = 6 per group), and the RNA-seq dataset was used to generate Volcano plot and KEGG pathway enrichment bubble plots of DEGs. (C,D) mRNA and protein levels of HARS, WARS, SerRS, LARS, and KARS were assessed in liver tissues at 7 and 11 days post-surgery using (C) RT-qPCR and (D) immunoblotting. (E) The band intensities were quantified using ImageJ, normalized to the loading controls. (F) Immunohistochemistry was used to visualize LARS expression. Scale bar = 100 μm. (G) AML-12 cells were stimulated with 400 µM TCA for 24 h, the LARS protein and mRNA levels were detected. Data are denoted as mean ± SEM of six independent experiments (n = 6). Statistical significances were assessed utilizing Student’s t-test. *P < 0.05. LARS was upregulated in BDL mouse liver tissues. (A,B) Liver tissues were collected 7 days after sham or BDL surgery (n = 6 per group), and the RNA-seq dataset was used to generate Volcano plot and KEGG pathway enrichment bubble plots of DEGs. (C,D) mRNA and protein levels of HARS, WARS, SerRS, LARS, and KARS were assessed in liver tissues at 7 and 11 days post-surgery using (C) RT-qPCR and (D) immunoblotting. (E) The band intensities were quantified using ImageJ, normalized to the loading controls. (F) Immunohistochemistry was used to visualize LARS expression. Scale bar = 100 μm. (G) AML-12 cells were stimulated with 400 µM TCA for 24 h, the LARS protein and mRNA levels were detected. Data are denoted as mean ± SEM of six independent experiments (n = 6). Statistical significances were assessed utilizing Student’s t-test. *P < 0.05. HARS, WARS, SerRS, LARS, and KARS levels at both the mRNA and protein levels were subsequently examined in cholestatic liver tissues. Mice subjected to either BDL or sham operations had their liver samples collected on days 7 and 11 post-surgery. RT-qPCR and immunoblot analyses revealed that LARS mRNA and protein expression were markedly upregulated in the livers of BDL mice in comparison to sham-operated controls, while the expression levels of other ARSs did not exhibit statistically significant changes. Furthermore, LARS expression was found to be markedly higher in the BDL 11-day group relative to the BDL 7-day group, suggesting a time-dependent increase in LARS levels corresponding to the progression of liver injury (Fig. 1C to E). IHC staining corroborated these findings by demonstrating a progressive elevation in LARS protein expression with prolonged BDL exposure (Fig. 1F). In TCA-stimulated AML-12 cells, we observed that both the protein and mRNA expression levels of LARS were significantly upregulated compared to the control group (Fig. 1G). Microarray datasets (GSE166867, GSE36066, GSE182235 and GSE186444) procured from the Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) were further analyzed. These datasets include liver tissues collected from mice following BDL or sham-operated mice serving as controls, and liver tissues from healthy donor and biliary atresia patients. In the GSE166867 dataset, 8,259 DEGs were identified in the BDL group versus the Sham group, encompassing 3,893 upregulated and 4,366 downregulated genes. Analysis of the GSE36066 dataset revealed 7,958 DEGs (3,759 upregulated and 4,199 downregulated), while 7,452 DEGs were identified in the GSE182235 dataset (3,401 upregulated and 4,051 downregulated). Representative heatmaps and volcano plots are illustrated in Fig. 2A and B. Venn diagram analysis across the three datasets demonstrated that LARS expression was consistently and markedly upregulated in all three cohorts (Fig. 2C). Analysis of the GSE186444 dataset from liver tissues of healthy donors and patients with biliary atresia revealed 2,023 DEGs (1,635 upregulated and 388 downregulated), the heatmap and volcano plots are shown in Fig. 2D. Consistent with the findings in mice tissues, the expression level of LARS was also significantly upregulated in human cholestatic liver tissues. Fig. 2Bioinformatics reveals upregulation of LARS expression in cholestatic livers. (A-C) Transcriptome sequencing datasets (GSE166867, GSE36066, GSE182235) of BDL mouse livers were analyzed to identify DEGs, (A) heatmap and (B) volcano plot display the DEGs. (C) Lars’ mRNA levels in each dataset were quantified. (D) Transcriptome sequencing of GSE186444 contains liver tissues of healthy donor and biliary atresia patients, the heatmap and volcano plot of DEGs, Lars mRNA levels were shown. Data are denoted as mean ± SEM. Statistical significances were assessed utilizing Student’s t-test. *P < 0.05. Bioinformatics reveals upregulation of LARS expression in cholestatic livers. (A-C) Transcriptome sequencing datasets (GSE166867, GSE36066, GSE182235) of BDL mouse livers were analyzed to identify DEGs, (A) heatmap and (B) volcano plot display the DEGs. (C) Lars’ mRNA levels in each dataset were quantified. (D) Transcriptome sequencing of GSE186444 contains liver tissues of healthy donor and biliary atresia patients, the heatmap and volcano plot of DEGs, Lars mRNA levels were shown. Data are denoted as mean ± SEM. Statistical significances were assessed utilizing Student’s t-test. *P < 0.05. LARS deficiency ameliorates CLI in BDL mice Given that LARS expression is markedly elevated in the liver tissues of BDL mice, the impact of LARS knockdown on CLI was further investigated using a murine model, and the experimental flowchart is presented in Fig. 3A. To validate the role of LARS in BDL-induced CLI, pAAV-U6-shRNA-CMV-EGFP-WPRE vectors encoding shLARS or shNC were administered, and a substantial reduction in LARS mRNA and protein levels was detected in the livers of shLARS-treated mice three weeks post-injection (Fig. 3B,C). Serum ALT, AST, and ALP levels were markedly diminished in the shLARS BDL group versus the shNC BDL group (Fig. 3D). The mRNA expression levels of the inflammatory cytokine Tnf-α, Il-1β and Il-6 in liver tissues exhibited a trend similar to that of the serum biochemical indicators (Fig. 3E). Histopathological examination indicated that necrotic damage was less prominent in livers from the shLARS BDL group compared to the shNC BDL group, liver fibrosis, assessed by Sirius red staining, was notably reduced in shLARS mice relative to shNC mice following BDL. Consistently, TUNEL staining and IHC detection of cleaved caspase-3 revealed a significant decrease in DNA fragmentation and apoptotic hepatocytes in shLARS BDL livers compared with shNC controls (Fig. 3F). Additionally, BDL led to the accumulation of TBA in both serum and hepatic tissues, whereas shLARS induced a significant decrease in TBA levels compared to the shNC group (Fig. 3G). BA spectrum analysis revealed that BDL significantly disrupted BA homeostasis, whereas the levels of the altered BAs were substantially restored in the shLARS group (Fig. 3H). Fig. 3LARS knockdown ameliorates cholestatic liver injury and fibrosis in BDL mice. (A) Diagram illustrates the mouse model employed for LARS knockdown. C57BL/6J mice were injected via the tail vein with pAAV-shLARS or pAAV-shNC for 3 weeks, followed by 1 week of BDL. (B,C) LARS expression was measured in liver tissues by RT-qPCR and WB. (D) Serum ALT, AST, and ALP levels are shown. (E) The mRNA levels of Tnf-α, Il-1βand Il-6 in liver tissues were detected using RT-qPCR. (F) Histological staining (H&E and Sirius red), cleaved caspase-3 immunohistochemistry and TUNEL assay were performed on liver sections from experimental groups. (G) Serum and hepatic TBA levels. (H) The concentrations of liver BAs were detected using UHPLC/MS. Scale bar = 100 μm. n = 6 per group. Data are denoted as mean ± SEM. Statistical significance was determined by ANOVA followed by Tukey’s post-hoc test. *P < 0.05. LARS knockdown ameliorates cholestatic liver injury and fibrosis in BDL mice. (A) Diagram illustrates the mouse model employed for LARS knockdown. C57BL/6J mice were injected via the tail vein with pAAV-shLARS or pAAV-shNC for 3 weeks, followed by 1 week of BDL. (B,C) LARS expression was measured in liver tissues by RT-qPCR and WB. (D) Serum ALT, AST, and ALP levels are shown. (E) The mRNA levels of Tnf-α, Il-1βand Il-6 in liver tissues were detected using RT-qPCR. (F) Histological staining (H&E and Sirius red), cleaved caspase-3 immunohistochemistry and TUNEL assay were performed on liver sections from experimental groups. (G) Serum and hepatic TBA levels. (H) The concentrations of liver BAs were detected using UHPLC/MS. Scale bar = 100 μm. n = 6 per group. Data are denoted as mean ± SEM. Statistical significance was determined by ANOVA followed by Tukey’s post-hoc test. *P < 0.05. LARS overexpression aggravates CLI in BDL mice Considering that LARS knockdown alleviates CLI, the potential exacerbating effect of its overexpression on BDL-induced liver injury was further examined. To this end, a recombinant pcADV-EF1-mNeonGreen-CMV-3×Flag vector was employed to induce LARS overexpression in mice. Per the RT-qPCR data, WB analysis confirmed a pronounced elevation in LARS protein expression (Fig. 4A, B). Additionally, serum ALT, AST, and ALP levels were markedly elevated following LARS overexpression, indicating exacerbation of liver injury (Fig. 4C). The mRNA expression levels of the inflammatory cytokine Tnf-α, Il-1β and Il-6 in liver tissues exhibited a trend similar to that of the serum biochemical indicators (Fig. 4D). As anticipated, pAd-LARS mice exhibited a significant increase in BDL-induced hepatic necrosis, fibrosis, and apoptotic cell rate (Fig. 4E) and TBA levels (Fig. 4F) versus vector control mice. BAs spectrum analysis demonstrated that, LARS overexpression exacerbates the alterations BA homeostasis induced by BDL (Fig. 4G). Collectively, these observations suggest that hepatic overexpression of LARS intensifies BDL-induced hepatocyte injury. Fig. 4LARS overexpression exacerbates cholestastic liver injury and fibrosis in BDL mice. (A,B) Mice were injected with pAd-LARS or pAd-Vector for 7 d before undergoing BDL for another 7 d. RT-qPCR and WB were utilized to examine the LARS mRNA and protein levels in liver tissues. (D) Serum ALT, AST, and ALP levels were analyzed. (E) The mRNA levels of Tnf-α, Il-1β and Il-6 in liver tissues were detected using RT-qPCR. (E) Liver sections were stained with H&E, Sirius red, cleaved caspase-3 immunohistochemistry and TUNEL assay. (F) Serum and hepatic TBA levels. (G) The concentrations of liver BAs were detected with UHPLC/MS. Scale bar = 100 μm. n = 6 per group. Data are denoted as mean ± SEM. Statistical significance was determined by ANOVA followed by Tukey’s post-hoc test. *P < 0.05. LARS overexpression exacerbates cholestastic liver injury and fibrosis in BDL mice. (A,B) Mice were injected with pAd-LARS or pAd-Vector for 7 d before undergoing BDL for another 7 d. RT-qPCR and WB were utilized to examine the LARS mRNA and protein levels in liver tissues. (D) Serum ALT, AST, and ALP levels were analyzed. (E) The mRNA levels of Tnf-α, Il-1β and Il-6 in liver tissues were detected using RT-qPCR. (E) Liver sections were stained with H&E, Sirius red, cleaved caspase-3 immunohistochemistry and TUNEL assay. (F) Serum and hepatic TBA levels. (G) The concentrations of liver BAs were detected with UHPLC/MS. Scale bar = 100 μm. n = 6 per group. Data are denoted as mean ± SEM. Statistical significance was determined by ANOVA followed by Tukey’s post-hoc test. *P < 0.05. LARS knockdown alleviates TCA-induced apoptosis in AML-12 cells To examine the mechanistic importance of LARS in TCA-treated hepatocytes, LARS expression was silenced using siRNAs, and knockdown efficiency was validated by RT-qPCR. Relative to the siNC group, siLARS treatment markedly reduced LARS mRNA expression levels (Fig. 5A). Cell viability, assessed via CCK-8 assay, was markedly diminished following TCA exposure. However, LARS silencing markedly restored cell viability (Fig. 5B). WB analysis demonstrated that the Bax/Bcl-2 ratio and cleaved caspase-3 levels were elevated in TCA-treated AML-12 cells, whereas these apoptotic markers were reversed upon LARS knockdown (Fig. 5C and D). DHE staining revealed that the proportion of ROS-positive cells was diminished in the siLARS group (Fig. 5E). Flow cytometry results further confirmed a significant decline in the apoptotic cell population following LARS silencing (Fig. 5F). Inflammatory cytokine expression was measured by RT-qPCR, which showed that 24 h TCA treatment markedly upregulated Tnf-α, Il-6, and Il-1β mRNA levels in AML-12 cells. In contrast to the siNC + TCA group, the siLARS + TCA group displayed markedly reduced expression of these inflammatory factors (Fig. 5G). Fig. 5LARS knockdown reduced TCA-induced apoptosis in AML-12 cells. AML-12 cells underwent transfection with siNC or siLARS for 48 h. (A) LARS mRNA expression was assessed via RT-qPCR. Subsequently, cells received treatment with 100 µM TCA for 24 h. (B) Cell viability was evaluated using the CCK-8 assay. (C) Protein expression of caspase-3, cleaved caspase-3, Bcl-2, bax and LARS was assessed via immunoblot. (D) The band intensities were quantified using ImageJ, normalized to the loading controls. (E) Intracellular ROS concentrations were examined utilizing a DHE probe and visualized through fluorescence microscopy, with quantitative assessment of fluorescence intensity. (F) Apoptotic rate was evaluated through Annexin V-APC/PI staining and FCM assay, with quantitative assessment of apoptotic cells. (G) The mRNA expression of Tnf-α, Il-6, and Il-1β in AML-12 cells was determined via RT-qPCR. Data are denoted as mean ± SEM. Statistical significance was determined by ANOVA followed by Tukey’s post-hoc test. *P < 0.05. LARS knockdown reduced TCA-induced apoptosis in AML-12 cells. AML-12 cells underwent transfection with siNC or siLARS for 48 h. (A) LARS mRNA expression was assessed via RT-qPCR. Subsequently, cells received treatment with 100 µM TCA for 24 h. (B) Cell viability was evaluated using the CCK-8 assay. (C) Protein expression of caspase-3, cleaved caspase-3, Bcl-2, bax and LARS was assessed via immunoblot. (D) The band intensities were quantified using ImageJ, normalized to the loading controls. (E) Intracellular ROS concentrations were examined utilizing a DHE probe and visualized through fluorescence microscopy, with quantitative assessment of fluorescence intensity. (F) Apoptotic rate was evaluated through Annexin V-APC/PI staining and FCM assay, with quantitative assessment of apoptotic cells. (G) The mRNA expression of Tnf-α, Il-6, and Il-1β in AML-12 cells was determined via RT-qPCR. Data are denoted as mean ± SEM. Statistical significance was determined by ANOVA followed by Tukey’s post-hoc test. *P < 0.05. LARS overexpression exacerbates TCA-induced apoptosis in AML-12 cells To evaluate the functional importance of LARS, overexpression vectors were utilized to induce its expression in AML-12 cells. The effectiveness of LARS expression enhancement was subsequently confirmed through RT-qPCR measurements (Fig. 6A). Assessment via CCK-8 assay demonstrated that cells with elevated LARS expression exhibited substantially decreased viability compared to vector control (Fig. 6B). Western blot examination indicated heightened levels of Bax/Bcl-2 ratio and cleaved caspase-3 proteins in cells expressing excess LARS versus Vector controls (Fig. 6C and D). Upon TCA stimulation, enhanced LARS expression resulted in notable elevation of intracellular ROS concentrations (Fig. 6E). Analysis by flow cytometry demonstrated a considerable increase in cells undergoing apoptosis (Fig. 6F). Additionally, elevated LARS expression triggered substantial increases in Tnf-α, Il-6, and Il-1β transcript levels within AML-12 cells (Fig. 6G). Fig. 6LARS overexpression increased TCA-induced apoptosis in AML-12 cells. AML-12 cells underwent transfection with Flag or LARS expression vector for 48 h. (A) RT-qPCR was employed to assess the mRNA levels of LARS. Subsequently, cells received stimulation with 100 µM TCA for 24 h. (B) CCK-8 assay was utilized to evaluate cell viability. (C) Immunoblot analysis was performed to determine the protein levels of caspase-3, cleaved caspase-3, Bcl-2, Bax, and LARS. (D) The band intensities were quantified using ImageJ, normalized to the loading controls. (E) Intracellular ROS levels were examined using a DHE probe and visualized via fluorescence microscopy, with quantitative analysis of fluorescence intensity. (F) Annexin V-APC/PI staining combined with FCM assay was conducted to assess the apoptosis rate, along with quantitative analysis of apoptotic cells. (G) RT-qPCR was employed to measure the mRNA levels of Tnf-α, Il-6, and Il-1β in AML-12 cells. Data are denoted as mean ± SEM. Statistical significances were assessed utilizing Student’s t-test. *P < 0.05. LARS overexpression increased TCA-induced apoptosis in AML-12 cells. AML-12 cells underwent transfection with Flag or LARS expression vector for 48 h. (A) RT-qPCR was employed to assess the mRNA levels of LARS. Subsequently, cells received stimulation with 100 µM TCA for 24 h. (B) CCK-8 assay was utilized to evaluate cell viability. (C) Immunoblot analysis was performed to determine the protein levels of caspase-3, cleaved caspase-3, Bcl-2, Bax, and LARS. (D) The band intensities were quantified using ImageJ, normalized to the loading controls. (E) Intracellular ROS levels were examined using a DHE probe and visualized via fluorescence microscopy, with quantitative analysis of fluorescence intensity. (F) Annexin V-APC/PI staining combined with FCM assay was conducted to assess the apoptosis rate, along with quantitative analysis of apoptotic cells. (G) RT-qPCR was employed to measure the mRNA levels of Tnf-α, Il-6, and Il-1β in AML-12 cells. Data are denoted as mean ± SEM. Statistical significances were assessed utilizing Student’s t-test. *P < 0.05. BA accumulation induced the activation of general control nonderepressible 2 (GCN2) To evaluate the impact of BA accumulation on the ISR signaling pathway, protein expression was analyzed via WB in liver tissues collected at 7 and 11 days post-BDL, as well as in AML-12 cells exposed to 100 µM TCA for 24 h. The results indicated that both BDL and TCA exposure led to the activation of the protein kinase-like endoplasmic reticulum kinase (PERK) and GCN2 signaling branches, as evidenced by increased phosphorylation of both PERK and GCN2 levels (Fig. 7A and B). Additionally, RT-qPCR analysis revealed that GCN2 mRNA expression was markedly upregulated in both BDL-treated liver tissues and TCA-stimulated AML-12 cells (Fig. 7C). Fig. 7BA stimulation upregulates LARS expression and activates the ISR pathway. (A) Immunoblot analysis was performed to detect LARS, GCN2, P-PERK, PERK, CHOP, P-eIF2α, eIF2α, and ATF4 protein levels in hepatic tissues following BDL for 7 d and 11 d, as well as in AML-12 cells treated with 100 µM TCA for 24 h. GAPDH served as the loading control. (B) The band intensities were quantified using ImageJ, normalized to the loading controls. (C) RT-qPCR was utilized to examine Gcn2 mRNA levels in hepatic tissues and AML-12 cells. n = 6 per group. Data are denoted as mean ± SEM. Statistical significances were assessed utilizing Student’s t-test. *P < 0.05. BA stimulation upregulates LARS expression and activates the ISR pathway. (A) Immunoblot analysis was performed to detect LARS, GCN2, P-PERK, PERK, CHOP, P-eIF2α, eIF2α, and ATF4 protein levels in hepatic tissues following BDL for 7 d and 11 d, as well as in AML-12 cells treated with 100 µM TCA for 24 h. GAPDH served as the loading control. (B) The band intensities were quantified using ImageJ, normalized to the loading controls. (C) RT-qPCR was utilized to examine Gcn2 mRNA levels in hepatic tissues and AML-12 cells. n = 6 per group. Data are denoted as mean ± SEM. Statistical significances were assessed utilizing Student’s t-test. *P < 0.05. LARS regulates the ISR signaling pathway To validate the protective role of LARS knockdown against BA-induced hepatocellular injury, the ISR signaling pathway was examined utilizing RT-qPCR and immunoblotting. RT-qPCR analysis revealed that in vivo silencing of LARS markedly suppressed the BDL-induced upregulation of GCN2, ATF4, and CHOP mRNA levels (Fig. 8A). To validate antibody specificity of ATF4 and CHOP, the AML-12 cells were transfected with siNC or siLARS for 48 h, and then stimulated with 10 µg/mL Tm and 1 µM Tg for 2 h before harvest. We found that, ATF4 and CHOP were undetectable in AML12 cells under baseline conditions, Tm and Tg stimulation significantly induced their expression (Fig. 8B and C), indicating the well specific of the antibodies. Western blot assay also showed that knockdown LARS decreased the ATF4 and CHOP protein levels in liver tissues. Furthermore, the phosphorylation of GCN2 and eIF2α, an essential component of ISR, was markedly increased upon BDL treatment, while decreased in shLARS liver tissues (Fig. 8D). A comparable suppressive effect was also observed in AML-12 cells transfected with LARS-targeting siRNA, as demonstrated by the reduction in both protein and mRNA levels (Fig. 8E and F). These results indicated that, LARS knockdown significantly reduced the protein levels of ATF4, CHOP, P-eIF2α, and P-GCN2 both in vivo and in vitro, suggesting that LARS modulates the ISR signaling cascade. Fig. 8LARS knockdown inhibits the BA induced activation of the ISR pathway. (A) pAAV-shLARS or pAAV-shNC were tail vein injected into C57BL/6J mice for 21 d, followed by BDL for 7 d. The mRNA levels of Lars, Pkr, Gcn2, Atf4, Chop, and Erdj4 were detected with RT-qPCR; (B-C) AML-12 cells were transfected with siNC or siLARS for 48 h, and then stimulated with 10 µg/mL Tm (B) and 1 µM Tg (C) for 2 h before harvest, the ATF4 and CHOP protein levels were detected using immunoblot; (D) the LARS, P-GCN2, GCN2, ATF4, CHOP, P-eIF2α, and eIF2α protein levels in liver tissues were analyzed using immunoblot. (E-F) AML-12 cells were transfected with siNC or siLARS for 48 h, and then stimulated with 100 µM TCA for 24 h. The protein levels of LARS, P-GCN2, GCN2, ATF4, CHOP, P-eIF2α, and eIF2α were analyzed using immunoblot (F), and the mRNA levels of Lars, Pkr, Gcn2, Atf4, Chop, and Erdj4 were detected with RT-qPCR (F). GAPDH was used as a loading control. Data are denoted as mean ± SEM. Statistical significances were assessed utilizing Student’s t-test. *P < 0.05. LARS knockdown inhibits the BA induced activation of the ISR pathway. (A) pAAV-shLARS or pAAV-shNC were tail vein injected into C57BL/6J mice for 21 d, followed by BDL for 7 d. The mRNA levels of Lars, Pkr, Gcn2, Atf4, Chop, and Erdj4 were detected with RT-qPCR; (B-C) AML-12 cells were transfected with siNC or siLARS for 48 h, and then stimulated with 10 µg/mL Tm (B) and 1 µM Tg (C) for 2 h before harvest, the ATF4 and CHOP protein levels were detected using immunoblot; (D) the LARS, P-GCN2, GCN2, ATF4, CHOP, P-eIF2α, and eIF2α protein levels in liver tissues were analyzed using immunoblot. (E-F) AML-12 cells were transfected with siNC or siLARS for 48 h, and then stimulated with 100 µM TCA for 24 h. The protein levels of LARS, P-GCN2, GCN2, ATF4, CHOP, P-eIF2α, and eIF2α were analyzed using immunoblot (F), and the mRNA levels of Lars, Pkr, Gcn2, Atf4, Chop, and Erdj4 were detected with RT-qPCR (F). GAPDH was used as a loading control. Data are denoted as mean ± SEM. Statistical significances were assessed utilizing Student’s t-test. *P < 0.05. LARS deficiency reverse BDL-induced AAs metabolic disturbances and alterations in tRNA charging ratios We then measured the levels of 25 circulating AAs in liver tissues of each groups. The PCA scores plot illustrated significant alterations in AAs profiles in those exposed to BDL (Fig. 9A), and the heatmap in Fig. 9B illustrates the relative abundance profiles of all detected amino acids. Specifically, the concentrations of L-Leucine in liver tissues was significantly decreased after BDL surgery, knockdown LARS ameliorated this consequence of BDL (Fig. 9C). Subsequently, the effects of cellular amino acid levels on the charging ratio of tRNALeu were examined. Inhibition of translation was expected to increase the charging ratio of tRNALeu because it would reduce amino acid consumption. We found that, BDL treatment decreased the charging ratio of tRNALeu, knockdown LARS in liver tissues maintained the charging ratio (Fig. 9D). These results indicated that, cholestasis induced by BDL reduces intracellular free leucine levels in hepatocytes, leading to the accumulation of large amounts of unloaded tRNA due to substrate insufficiency for LARS, knockdown of LARS elevates intracellular leucine levels, increases the tRNA charging rate, and promotes protein biosynthesis in hepatocyte. Additionally, AML-12 cells treatment with ISRIB significantly abolished the hepatic protective effects of LARS knockdown (Fig. 9E), confirming that the ISR pathway is indeed a critical mediator of the injury. Fig. 9LARS on BDL-induced AAs metabolic disturbances and alterations in tRNA charging ratios. (A,B) C57BL/6J mice were injected with pAAV-shLARS or pAAV-shNC via tail vein for 21 d, followed by BDL for 7 d, the PCA analysis and heatmap of 25 amino acids in each group. (C) The L-Leucine contents in each group. (D) Charging ratios of tRNALeu(CUG) in liver tissues after treatment with BDL. (E) AML-12 cells were transfected with siNC or siLARS for 24 h, then pretreated with 250 nM ISRIB for 1 h before the addition of 400 µM TCA for another 24 h, cell viability was detected with CCK-8 assay. (F) AML-12 cells were transfected with siNC or siGCN2 for 48 h, the GCN2 mRNA and protein levels were detected with western blot and RT-qPCR. (G) AML-12 cells were transfected with LARS overexpression vector or siGCN2 for 24 h, and then stimulated with 400 µM TCA for another 24 h, the cell viability was measured with CCK-8 assay. Data are denoted as mean ± SEM. Statistical significances were assessed utilizing Student’s t-test. n = 6, *P < 0.05. LARS on BDL-induced AAs metabolic disturbances and alterations in tRNA charging ratios. (A,B) C57BL/6J mice were injected with pAAV-shLARS or pAAV-shNC via tail vein for 21 d, followed by BDL for 7 d, the PCA analysis and heatmap of 25 amino acids in each group. (C) The L-Leucine contents in each group. (D) Charging ratios of tRNALeu(CUG) in liver tissues after treatment with BDL. (E) AML-12 cells were transfected with siNC or siLARS for 24 h, then pretreated with 250 nM ISRIB for 1 h before the addition of 400 µM TCA for another 24 h, cell viability was detected with CCK-8 assay. (F) AML-12 cells were transfected with siNC or siGCN2 for 48 h, the GCN2 mRNA and protein levels were detected with western blot and RT-qPCR. (G) AML-12 cells were transfected with LARS overexpression vector or siGCN2 for 24 h, and then stimulated with 400 µM TCA for another 24 h, the cell viability was measured with CCK-8 assay. Data are denoted as mean ± SEM. Statistical significances were assessed utilizing Student’s t-test. n = 6, *P < 0.05. To further investigate the impact of GCN2 on LARS function, we transfected LARS-overexpressing AML-12 cells with siRNA targeting GCN2, followed by TCA stimulation and assessment of cell viability using the CCK-8 assay. The transfection efficiency of siRNA was assessed by Western blot and RT-qPCR (Fig. 9F). The results demonstrated that in the absence of TCA stimulation, neither LARS overexpression nor GCN2 knockdown alone significantly affected the viability of AML-12 cells. However, under TCA-stimulated conditions, LARS overexpression significantly reduced cell viability, whereas GCN2 knockdown led to a significant increase. Notably, compared to the LARS + TCA group, the simultaneous overexpression of LARS and knockdown of GCN2 resulted in increased cell viability (Fig. 9G). This indicates that GCN2 knockdown reverses the suppressive effect of LARS overexpression on AML-12 cell viability, and the effect of LARS on cell viability depends on the expression level of GCN2. Discussion The ARSs family comprises indispensable enzymes responsible for catalyzing the conjugation of amino acids to their corresponding tRNAs, a fundamental initial step in protein synthesis26,27. Moreover, they serve pivotal functions in modulating the expression of genes associated with cellular proliferation, differentiation, and apoptosis28,29. LARS, functioning as a component of the multi-tRNA synthetase complex, is essential for the accurate charging of leucine to its cognate tRNA. Beyond its canonical role, LARS serves as a non-traditional effector associated with mTORC1, being indispensable for leucine-mediated mTORC1 activation. This dual functionality indicates that LARS acts not only as a synthetase but also as an intracellular sensor of leucine for mTORC1 signaling30. In this investigation, a novel hepatoprotective role of LARS in CLI was elucidated, alongside the underlying molecular mechanisms. It was demonstrated that hepatocellular exposure to BAs elevated LARS expression. Silencing of LARS attenuated cellular injury, whereas its overexpression exacerbated the damage. The absence of LARS exhibited a protective hepatic effect by downregulating GCN2 expression, which subsequently suppressed eIF2α phosphorylation and ultimately inhibited activation of the ISR signaling pathway. A negative regulatory correlation between LARS expression and ISR signaling was thereby established. These findings provide a conceptual basis for considering LARS as a potential therapeutic target for CLI and fibrosis. ISR activation has been documented in multiple hepatic disorders, encompassing non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, viral hepatitis, HCC, acetaminophen-induced acute liver injury, and CLI31–35. These conditions are frequently characterized by hepatocellular steatosis and apoptosis, suggesting a potential association between ISR and disturbances in hepatocyte metabolic equilibrium and programmed cell death. ISR functions as a compensatory cellular mechanism in response to a spectrum of metabolic insults, such as endoplasmic reticulum stress and amino acid scarcity, and is implicated in regulating both cellular proliferation and survival36,37. Depending on the nature of the stressor, ISR is triggered via one of four eIF2α-specific kinases, GCN238, PERK37, double-stranded RNA-dependent protein kinase39, and heme-regulated inhibitor40. These kinases converge mechanistically to phosphorylate eIF2α at the Ser51 residue, leading to a general attenuation of global protein translation, while selectively facilitating the translation of ATF4 mRNA41. ATF4 subsequently enhances transcriptional expression of stress-adaptive genes involved in protein folding, amino acid utilization, and redox homeostasis42,43. In this context, it was observed that the depletion of LARS suppressed ISR signaling in BA-stimulated hepatocytes by downregulating GCN2 expression. GCN2, a highly conserved member of the eIF2AK family, has been recognized for its essential involvement in maintaining amino acid homeostasis across species ranging from yeast to humans44. Under conditions of amino acid deprivation, particularly leucine scarcity, the histidyl-tRNA synthetase-like domain of GCN2 interacts with uncharged tRNA, a process that subsequently triggers the phosphorylation of eIF2α. This phosphorylation event modulates gene transcription and translation, governs intracellular protein synthesis, and contributes to the restoration of amino acid equilibrium45. In addition to amino acid depletion, various stressors, including ultraviolet irradiation, viral infections, and proteasome inhibition, have been demonstrated to activate GCN2, either through elevation of uncharged tRNA levels or through induction of ribosomal stalling46. GCN2 has also been implicated in a broad spectrum of physiological and pathological contexts, encompassing glucolipid metabolism, innate immune responses, oncogenesis, and cognitive processes such as memory formation47–49. A previous study demonstrated that GCN2 becomes activated under amino acid deprivation through the intracellular accumulation of deacylated tRNA, which serves as an intrinsic indicator of amino acid insufficiency. This deacylated tRNA is believed to interact with the C-terminal HisRS-like domain of GCN2, a region that also contributes to autoinhibition of its kinase domain50. Upon amino acid depletion, the stress-sensing kinase GCN2 modulates protein production through eIF2α phosphorylation51, and the activation of GCN2 further promotes the expression of the transcription factor ATF452. The GCN2-ATF4 axis has been implicated in the regulation of oxidative stress by maintaining ROS equilibrium in response to mitochondrial dysfunction53,54. Recent investigations have revealed that GCN2 is broadly expressed across multiple systems and serves a critical function in modulating inflammatory responses. It has been reported that GCN2 activity attenuates inflammation55 and is implicated in various inflammatory conditions, such as osteoarthritis and allergic airway inflammation56,57. Moreover, GCN2 participates in the pathogenesis of liver-related disorders. It modulates insulin sensitivity and enhances lipid metabolic pathways, thereby contributing to the progression of metabolic conditions including diabetes and non-alcoholic fatty liver disease58,59. Additionally, GCN2 facilitates hepatic fibrosis progression through the induction of collagen synthesis by modulating hepatic stellate cell activation60. In this study, it was observed that GCN2 expression was markedly increased following BA stimulation. However, LARS deficiency led to a reduction in GCN2 expression under these conditions, whereas no significant effect was detected in the absence of BA stimulation. The molecular mechanism underlying this regulation remains to be elucidated. Conclusion In conclusion, this study demonstrated that LARS within hepatocytes functions as a pivotal regulator contributing to the prevention of CLI. The underlying molecular mechanism was involved that, cholestasis induced by BDL reduces intracellular free leucine levels in hepatocytes. This leucine deficiency results in the accumulation of unloaded tRNALeu due to insufficient substrate for LARS, while concurrently inducing a compensatory upregulation of LARS protein expression. The accumulated unloaded tRNAs serve as danger signals that activate GCN2 kinase, leading to phosphorylation of eIF2α and subsequent selective translation of ATF4. This cascade ultimately initiates the ISR in hepatocytes, an adaptive program aimed at restoring amino acid homeostasis that may also induce apoptosis under conditions of excessive or unresolved stress. These findings indicate that LARS emerges as a potential treatment target for CLI, potentially offering novel strategies for the effective management of CLI and its related complications. While the existing literature supports that the ISR can transcriptionally control autophagy61, the precise functional role of autophagy in LARS-mediated hepatoprotection, whether as a downstream effector of the ISR or a coinciding parallel event, remains to be determined. Future studies employing autophagy inhibitors or hepatocyte-specific autophagy related gene knockout mice will be necessary to dissect this complex interplay. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1